Insulin-derived amyloidosis
Insulin-derived amyloidosis, also known as insulin ball, is a subcutaneous amyloid mass at the site of repeated insulin injections. Because patients may find injections to be less painful at the site of the amyloidosis, some inject directly into them instead of at a new site. Insulin absorption at s...
Gespeichert in:
| Veröffentlicht in: | Canadian Medical Association journal (CMAJ) 2022-12, Vol.194 (47), p.E1616-E1616 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | E1616 |
|---|---|
| container_issue | 47 |
| container_start_page | E1616 |
| container_title | Canadian Medical Association journal (CMAJ) |
| container_volume | 194 |
| creator | Kano, Yasuhiro |
| description | Insulin-derived amyloidosis, also known as insulin ball, is a subcutaneous amyloid mass at the site of repeated insulin injections. Because patients may find injections to be less painful at the site of the amyloidosis, some inject directly into them instead of at a new site. Insulin absorption at sites of insulin-derived amyloidosis is about one-third of that compared with other sites. Insulin-derived amyloidosis is uncommon and is often misdiagnosed as insulin injection--associated lipohypertrophy, which occurs in as many as 50% of patients. Ultrasonography, CT and magnetic resonance imaging may be used to distinguish between the 2 entities; however, a definitive diagnosis can only be made histologically. Both conditions can be managed by rotation of injection sites. Amyloidosis often regresses slowly after insulin injections are stopped, whereas lipohypertrophic lesions tend to resolve more quickly. Patients presenting with unexplained, worsening glycemic control should have their injection sites examined and blood glucose levels monitored regularly. |
| doi_str_mv | 10.1503/cmaj.220531 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2753667960</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A728397226</galeid><sourcerecordid>A728397226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c515t-b035b111924646a0a29c2f6175ee3c3ea4c5039fbb829212548d5f6e04a131753</originalsourceid><addsrcrecordid>eNqV0s1rFDEYBvBQlHatPXkURBREkVnzncmxFD8WSgVtzyGTeWebJTPZJjNi_3uzbLVd2UuTQyD88vBCHoReEDwnArNPrrerOaVYMHKAZoTXdUUZ1U_QDNcUV0xzeYSe5bzCZTGqDtERkwIrVesZerkY8hT8ULWQ_C9oX9v-NkTfxuzzc_S0syHDyd15jK6-fL48-1adf_-6ODs9r5wgYqwazERDCNGUSy4ttlQ72kmiBABzDCx3ZUzdNU1NNSVU8LoVnQTMLWFFsWP0fpu7TvFmgjya3mcHIdgB4pQNLUZKpSUu9O1_dBWnNJTpiuIKM8UxvVdLG8D4oYtjsm4Tak4VrZlWlMqiqj1qCQMkG-IAnS_XO_7NHu_W_sY8RPM9qOwWeu_2pn7YeVDMCL_HpZ1yNoufPx5hL3btuwf2GmwYr3MM0-jjkHfhxy10KeacoDPr5Hubbg3BZlMwsymY2Ras6Fd3HzA1PbT_7N9GsT_stcIr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2747037402</pqid></control><display><type>article</type><title>Insulin-derived amyloidosis</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Kano, Yasuhiro</creator><creatorcontrib>Kano, Yasuhiro</creatorcontrib><description>Insulin-derived amyloidosis, also known as insulin ball, is a subcutaneous amyloid mass at the site of repeated insulin injections. Because patients may find injections to be less painful at the site of the amyloidosis, some inject directly into them instead of at a new site. Insulin absorption at sites of insulin-derived amyloidosis is about one-third of that compared with other sites. Insulin-derived amyloidosis is uncommon and is often misdiagnosed as insulin injection--associated lipohypertrophy, which occurs in as many as 50% of patients. Ultrasonography, CT and magnetic resonance imaging may be used to distinguish between the 2 entities; however, a definitive diagnosis can only be made histologically. Both conditions can be managed by rotation of injection sites. Amyloidosis often regresses slowly after insulin injections are stopped, whereas lipohypertrophic lesions tend to resolve more quickly. Patients presenting with unexplained, worsening glycemic control should have their injection sites examined and blood glucose levels monitored regularly.</description><identifier>ISSN: 0820-3946</identifier><identifier>EISSN: 1488-2329</identifier><identifier>DOI: 10.1503/cmaj.220531</identifier><identifier>PMID: 36507789</identifier><language>eng</language><publisher>Canada: CMA Impact Inc</publisher><subject>Abdomen ; Amyloidosis ; Amyloidosis - diagnosis ; Complications and side effects ; Diabetes ; Diagnosis ; Humans ; Hypoglycemic Agents ; Iatrogenesis ; Injections ; Insulin ; Insulin - therapeutic use ; Patient outcomes ; Patients ; Risk factors ; Type 2 diabetes</subject><ispartof>Canadian Medical Association journal (CMAJ), 2022-12, Vol.194 (47), p.E1616-E1616</ispartof><rights>COPYRIGHT 2022 CMA Impact Inc.</rights><rights>Copyright CMA Impact, Inc. Dec 5, 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c515t-b035b111924646a0a29c2f6175ee3c3ea4c5039fbb829212548d5f6e04a131753</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36507789$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kano, Yasuhiro</creatorcontrib><title>Insulin-derived amyloidosis</title><title>Canadian Medical Association journal (CMAJ)</title><addtitle>CMAJ</addtitle><description>Insulin-derived amyloidosis, also known as insulin ball, is a subcutaneous amyloid mass at the site of repeated insulin injections. Because patients may find injections to be less painful at the site of the amyloidosis, some inject directly into them instead of at a new site. Insulin absorption at sites of insulin-derived amyloidosis is about one-third of that compared with other sites. Insulin-derived amyloidosis is uncommon and is often misdiagnosed as insulin injection--associated lipohypertrophy, which occurs in as many as 50% of patients. Ultrasonography, CT and magnetic resonance imaging may be used to distinguish between the 2 entities; however, a definitive diagnosis can only be made histologically. Both conditions can be managed by rotation of injection sites. Amyloidosis often regresses slowly after insulin injections are stopped, whereas lipohypertrophic lesions tend to resolve more quickly. Patients presenting with unexplained, worsening glycemic control should have their injection sites examined and blood glucose levels monitored regularly.</description><subject>Abdomen</subject><subject>Amyloidosis</subject><subject>Amyloidosis - diagnosis</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Diagnosis</subject><subject>Humans</subject><subject>Hypoglycemic Agents</subject><subject>Iatrogenesis</subject><subject>Injections</subject><subject>Insulin</subject><subject>Insulin - therapeutic use</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Risk factors</subject><subject>Type 2 diabetes</subject><issn>0820-3946</issn><issn>1488-2329</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqV0s1rFDEYBvBQlHatPXkURBREkVnzncmxFD8WSgVtzyGTeWebJTPZJjNi_3uzbLVd2UuTQyD88vBCHoReEDwnArNPrrerOaVYMHKAZoTXdUUZ1U_QDNcUV0xzeYSe5bzCZTGqDtERkwIrVesZerkY8hT8ULWQ_C9oX9v-NkTfxuzzc_S0syHDyd15jK6-fL48-1adf_-6ODs9r5wgYqwazERDCNGUSy4ttlQ72kmiBABzDCx3ZUzdNU1NNSVU8LoVnQTMLWFFsWP0fpu7TvFmgjya3mcHIdgB4pQNLUZKpSUu9O1_dBWnNJTpiuIKM8UxvVdLG8D4oYtjsm4Tak4VrZlWlMqiqj1qCQMkG-IAnS_XO_7NHu_W_sY8RPM9qOwWeu_2pn7YeVDMCL_HpZ1yNoufPx5hL3btuwf2GmwYr3MM0-jjkHfhxy10KeacoDPr5Hubbg3BZlMwsymY2Ras6Fd3HzA1PbT_7N9GsT_stcIr</recordid><startdate>20221205</startdate><enddate>20221205</enddate><creator>Kano, Yasuhiro</creator><general>CMA Impact Inc</general><general>CMA Impact, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>4T-</scope><scope>4U-</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FQ</scope><scope>8FV</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M3G</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20221205</creationdate><title>Insulin-derived amyloidosis</title><author>Kano, Yasuhiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c515t-b035b111924646a0a29c2f6175ee3c3ea4c5039fbb829212548d5f6e04a131753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Abdomen</topic><topic>Amyloidosis</topic><topic>Amyloidosis - diagnosis</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Diagnosis</topic><topic>Humans</topic><topic>Hypoglycemic Agents</topic><topic>Iatrogenesis</topic><topic>Injections</topic><topic>Insulin</topic><topic>Insulin - therapeutic use</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Risk factors</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kano, Yasuhiro</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Docstoc</collection><collection>University Readers</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Canadian Business & Current Affairs Database</collection><collection>Canadian Business & Current Affairs Database (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>British Nursing Index</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>CBCA Reference & Current Events</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Canadian Medical Association journal (CMAJ)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kano, Yasuhiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Insulin-derived amyloidosis</atitle><jtitle>Canadian Medical Association journal (CMAJ)</jtitle><addtitle>CMAJ</addtitle><date>2022-12-05</date><risdate>2022</risdate><volume>194</volume><issue>47</issue><spage>E1616</spage><epage>E1616</epage><pages>E1616-E1616</pages><issn>0820-3946</issn><eissn>1488-2329</eissn><abstract>Insulin-derived amyloidosis, also known as insulin ball, is a subcutaneous amyloid mass at the site of repeated insulin injections. Because patients may find injections to be less painful at the site of the amyloidosis, some inject directly into them instead of at a new site. Insulin absorption at sites of insulin-derived amyloidosis is about one-third of that compared with other sites. Insulin-derived amyloidosis is uncommon and is often misdiagnosed as insulin injection--associated lipohypertrophy, which occurs in as many as 50% of patients. Ultrasonography, CT and magnetic resonance imaging may be used to distinguish between the 2 entities; however, a definitive diagnosis can only be made histologically. Both conditions can be managed by rotation of injection sites. Amyloidosis often regresses slowly after insulin injections are stopped, whereas lipohypertrophic lesions tend to resolve more quickly. Patients presenting with unexplained, worsening glycemic control should have their injection sites examined and blood glucose levels monitored regularly.</abstract><cop>Canada</cop><pub>CMA Impact Inc</pub><pmid>36507789</pmid><doi>10.1503/cmaj.220531</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0820-3946 |
| ispartof | Canadian Medical Association journal (CMAJ), 2022-12, Vol.194 (47), p.E1616-E1616 |
| issn | 0820-3946 1488-2329 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2753667960 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Abdomen Amyloidosis Amyloidosis - diagnosis Complications and side effects Diabetes Diagnosis Humans Hypoglycemic Agents Iatrogenesis Injections Insulin Insulin - therapeutic use Patient outcomes Patients Risk factors Type 2 diabetes |
| title | Insulin-derived amyloidosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T12%3A45%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Insulin-derived%20amyloidosis&rft.jtitle=Canadian%20Medical%20Association%20journal%20(CMAJ)&rft.au=Kano,%20Yasuhiro&rft.date=2022-12-05&rft.volume=194&rft.issue=47&rft.spage=E1616&rft.epage=E1616&rft.pages=E1616-E1616&rft.issn=0820-3946&rft.eissn=1488-2329&rft_id=info:doi/10.1503/cmaj.220531&rft_dat=%3Cgale_proqu%3EA728397226%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2747037402&rft_id=info:pmid/36507789&rft_galeid=A728397226&rfr_iscdi=true |